/ Source: Reuters
Medtronic Inc.Wednesday said the U.S. Food and Drug Administration approved its latest neurostimulation device, SynergyPlus, to treat chronic pain.
The implantable pacemaker-like device is designed to give patients more control over the delivery of stimulation that blocks pain signals from reaching the brain.
Some 25 percent of the U.S. population, more than 70 million people, experience some form of chronic pain.
